Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer’s Disease Caused by a Genetic Mutation (DIAN-TU)

What is the study about?

This study examines people with no cognitive difficulties, mild cognitive impairment or Alzheimer’s disease who have genetics that causes Alzheimer’s disease. The goal is to test the safety and effectiveness of new study drugs, including antibodies targeting the protein amyloid-beta that builds up in the brains of people with Alzheimer’s disease. The study also aims to observe participants over time to monitor their daily function and to find ways to improve diagnosis.

 

 

Eligibility- Who can participate?

Participants must:

• be between the ages of 18 and 80 years
• know they have an Alzheimer’s disease-causing mutation or be unaware of their genetic status and have an autosomal dominant Alzheimer’s disease gene mutation in their family (genetic or autopsy report required)
• have no cognitive issues, mild cognitive impairment or mild dementia

 

Time requirement

Maximum of 17 visits over 4 years or less. The visits will include brain imaging, cognitive testing, neurological and physical exams, and taking biosamples (i.e. blood, urine)

 

TDRA Study Investigator

Dr. Mario Masellis

 

Video

Advances in Dementia Research Webinar- Listen to Dr. Mario Masellis (Co-Principal Investigator) discuss the DIAN-TU study in further detail: https://www.youtube.com/watch?v=UuvjuVTcEU4

 

More information

https://clinicaltrials.gov/ct2/show/NCT01760005

 

TDRA Site:

Sunnybrook Health Sciences Centre,

Address: 2075 Bayview Ave, Toronto, ON M4N 3M5

Age Group:

18 - 24, 25 - 29, 30 - 39, 40 - 49, 50 - 54, 55 - 59, 60 - 64, 65 - 69, 70 - 80

Target Population:

People with Alzheimer's disease genes